摘要
目的评估甘精胰岛素联合那格列奈治疗初诊2型糖尿病的疗效及安全性。方法初次诊断的HbA1c>8.0%的2型糖尿病患者75例,给予甘精胰岛素联合那格列奈治疗12周,比较治疗前后空腹血糖(FBG)、餐后2h血糖(2hPG)、糖化血红蛋白(HbA1c)及胰岛功能的变化。结果治疗后所有患者血糖及HbA1c均明显下降(P<0.01),餐后2h胰岛素、C肽水平、胰岛素分泌指数较治疗前明显升高,胰岛素抵抗指数较治疗前显著降低。结论甘精胰岛素联合那格列奈治疗初诊2型糖尿病,能理想控制血糖且胰岛功能得到部分恢复。
Objective To evaluate the efficacy and safety of nateglinide combined with insulin glargine in treatment of the new patients with type 2 diabetes. Methods Eighty-five patients with newly diagnosed type 2 diabetes were treated by nateglinide with insulin glargine injection 12 weeks. The changes of Fasting blood glucose（FBG）, 2 h postprandial blood glucose（2 hPG）, glycosylated hemoglobin（HbA 1 c） and B cell function were observed before and after the treatment. Results The levels of FBG,2 hPG, HbA 1 c and insulin resistance index after treatment significantly decreased （P〈0.01）. while postprandial 2 h insulin level, postprandial 2 h C-peptide level（2 h CP） and insulin secrete index was significantly higher then before（P〈0.01）. Conclusion Nateglinide combined with insulin glargine in treatment of the new patients with type 2 diabetes can ideally control glucose and significantly restored pancreatic islet B-cell function, reducing sugar toxicity.
出处
《当代医学》
2013年第10期32-33,共2页
Contemporary Medicine
